* Histogen Inc HSTO.OQ HSTO.O is expected to report
results on May 13.
* Refinitiv's mean analyst estimate for Histogen Inc is for a
loss of 15 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* Wall Street's median 12-month price target for Histogen Inc is
$5, about 80.8% above its last closing price of $0.96.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Dec. 31 2020 -0.35 -0.35 -0.26 Beat 25.7
Sep. 30 2019 -1.20 -1.00 Beat 16.7
Jun. 30 2019 -1.20 -1.20 -0.20 Beat 83.3
Mar. 31 2019 -1.16 -1.20 -1.40 Missed -16.7
This summary was machine generated May 11 at 20:00 GMT. All
figures in US dollars unless otherwise stated